News to PCSK9 Forum – The Editors’ Selection

Click here to forward this email to a colleague

New to PCSK9 Forum

News from the 14th Expert Meeting of the Editorial Board of PCSK9 Education and Research Forum

The latest insights from this Closed Expert Meeting focus on lipoprotein(a) and cholesterol crystals and plaque stability.

Focus on lipoprotein(a): Is there any potential risk with very low levels?

Dr Anne Langsted (Herlev and Gentofte Hospital, Copenhagen University Hospital, and the University of Copenhagen, Denmark) discusses the evidence, including findings from the Copenhagen General Population Study.

Watch the presentation »

Cholesterol crystals: Does their formation have implications for plaque stability and cardiovascular events?

Prof John Chapman (Pitié-Salpétrière University Hospital, Paris, France) discusses whether the processes involved in cholesterol homeostasis within plaque tissue have implications for regression of atherosclerotic plaque.

Watch the presentation »


	Hot off the press!

A new analysis from the FOURIER (Further Cardiovascular OUtcomes Research With PCSK9 Inhibition in Subjects with Elevated Risk) trial showed that evolocumab was equally effective in lowering the risk of cardiovascular events in Asian and non-Asian patients.

Read the report »

New study: No effect on cognitive function with alirocumab

Treatment for up to 96 weeks did not affect cognitive function, assessed using the CANTAB (Cambridge Neuropsychological Test Automated Battery) scale.

Read the report »

Like us

For the latest updates, PCSK9 news and analysis.

Hot topics, news and conference reports.

YouTube Channel

For videos, interviews and webcasts from leading experts.

Educational Partners
and Supporters